Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Septic Shock
NCT05969275Phase 2Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Feb 2024
- Primary completion
- Sep 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umbilical cord-derived mesenchymal stromal cells in septic shock (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Days free from mechanical ventilation and/or vasopressors and/or renal replacement therapy at 28 days. Started Feb 2024; status: recruiting.
02
Drugs
umbilical cord-derived mesenchymal stromal cells
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05969275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969275.